株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

米国の分子イメージング装置・放射性医薬品市場の分析:2023年までの予測

Analysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023

発行 Frost & Sullivan 商品コード 487817
出版日 ページ情報 英文 167 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.69円で換算しております。
Back to Top
米国の分子イメージング装置・放射性医薬品市場の分析:2023年までの予測 Analysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023
出版日: 2017年03月06日 ページ情報: 英文 167 Pages
概要

当レポートでは、米国の分子イメージング装置・放射性医薬品市場について調査分析し、市場概要、促進要因と抑制要因、セグメント別の市場分析、主要企業など、体系的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー:分子イメージング

第3章 エグゼクティブサマリー:放射性医薬品

第4章 市場概要

  • 分子イメージング
  • 放射性医薬品

第5章 促進要因と抑制要因:分子イメージング装置の総合市場

  • 市場促進要因
  • 市場抑制要因

第6章 PET/CT装置セグメント

  • 評価
  • 出荷台数予測
  • 収益予測
  • 動向分析
  • 市場シェア
  • 市場シェア分析

第7章 SPECT/CT装置セグメント

  • 評価
  • 出荷台数予測
  • 収益予測
  • 動向分析
  • 市場シェア
  • 市場シェア分析

第8章 PET/MR装置セグメント

  • 評価
  • 出荷台数予測
  • 収益予測
  • 動向分析
  • 市場シェア
  • 市場シェア分析

第9章 主要製品と主要企業

第10章 3大企業の最近の動向:PHILIPS HEALTHCARE

第11章 GE HEALTHCARE

第12章 SIEMENS HEALTHINEERS

第13章 注目すべき企業

  • NeuSoft
  • Toshiba America Medical Systems
  • Molecular Dynamics
  • UltraSPECT

第14章 分子イメージングの成長に影響を与えるその他の問題

第15章 主要技術と業界動向

第16章 促進要因と抑制要因:放射性医薬品の総合市場

  • 市場促進要因
  • 市場抑制要因

第17章 PET用放射性医薬品セグメント

  • 評価
  • 処置予測
  • 収益予測
  • 動向分析
  • 市場シェア
  • 市場シェア分析

第18章 SPECT用放射性医薬品セグメント

  • 評価
  • 処置予測
  • 収益予測
  • 動向分析
  • 市場シェア
  • 市場シェア分析

第19章 主要製品と企業

第20章 注目すべき主要企業

  • Siemens PETNET
  • IBA Molecular
  • Ionetix

第21章 主要な業界動向

第22章 オンコロジーにおける新たな放射性医薬品の役割

第23章 まとめ

第24章 付録

目次
Product Code: K0A6-54

Technology Advances and New Radiopharmaceuticals Maintain the Industry on a Growth Track

Molecular imaging can easily be described as the next frontier of medical imaging. In an era of value-based reimbursement, molecular imaging is set to play a significant role in quicker diagnosis, more accurate disease staging, and selection of targeted treatments. Launch of new radiopharmaceuticals across clinical areas other than cardiology and oncology such as neurology and orthopedics is also expected to drive greater adoption of molecular imaging as part of clinical care pathways.

However, molecular imaging continues to face several challenges, notably the high cost of molecular imaging modalities and image scans, competition from lower cost modalities such as CT and MRI, and concerns over future supply of Tc-99m, a key SPECT radiopharmaceutical used for cardiac scans. This study analyzes existing trends in the hybrid molecular imaging and diagnostic radiopharmaceuticals markets with an emphasis on understanding strategies employed by market participants to address these myriad challenges. It also assesses both these markets in the context of changing regulatory and reimbursement policies in order to provide future market trends. This analysis will be critical in helping market participants create long-term viable strategies in order to remain competitive and ensure continuous innovation.

This deliverable assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment. Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas. Companies that are in the process of developing software to improve quantitation accuracy, lower dosages, and reduce scan times for both PET and SPECT will be provided with key insights on how the molecular imaging market is growing as well as the factors that are required to facilitate greater adoption of PET and SPECT technologies.

image1


image2

Table of Contents

1. RESEARCH METHODOLOGY

  • 1. Research Methodology
  • 2. Research Methodology (continued)
  • 3. Scope of This Study

2. EXECUTIVE SUMMARY-MOLECULAR IMAGING

  • 1. Key Findings
  • 2. Key Findings (continued)
  • 3. Key Findings (continued)
  • 4. Key Findings (continued)
  • 5. Measurements-PET/CT
  • 6. Measurements-PET/CT (continued)
  • 7. Measurements-SPECT/CT
  • 8. Measurements-SPECT/CT (continued)
  • 9. Measurements-PET/MR

3. EXECUTIVE SUMMARY-RADIOPHARMACEUTICALS

  • 1. Key Findings
  • 2. Key Findings (continued)
  • 3. Measurements-PET
  • 4. Measurements-SPECT

4. MARKET OVERVIEW

  • 1. Scope of the Study-Molecular Imaging
  • 2. Scope of the Study-Radiopharmaceuticals
  • 3. Molecular Imaging-Segmentation
  • 4. Molecular Imaging-Definition
  • 5. Shift in Focus from Standalone to Hybrid Imaging
  • 6. Radiopharmaceuticals-Definitions
  • 7. Segmentation of Radiopharmaceuticals
  • 8. Segmentation of Radiopharmaceuticals (continued)
  • 9. Distribution of Radiopharmaceuticals
  • 10. US Radiopharmacy Facility Landscape 2016

5. DRIVERS AND RESTRAINTS-TOTAL MOLECULAR IMAGING EQUIPMENT MARKET

  • 1. Market Drivers
  • 2. Improvements in Quantitation Accuracy
  • 3. Role of Molecular Imaging in Personalized Medicine
  • 4. Molecular Imaging Entering Into New Therapeutic Areas
  • 5. Market Restraints
  • 6. Affordability of Hybrid Modalities Will Remain Key Issue
  • 7. Consolidations of Healthcare Providers
  • 8. Changing Hospital Procurement Models

6. PET/CT EQUIPMENT SEGMENT

  • 1. Measurements
  • 2. Unit Shipment Forecast
  • 3. Revenue Forecast
  • 4. Trend Analysis
  • 5. Market Share
  • 6. Market Share Analysis

7. SPECT/CT EQUIPMENT SEGMENT

  • 1. Measurements
  • 2. Unit Shipment Forecast
  • 3. Revenue Forecast
  • 4. Trend Analysis
  • 5. Market Share
  • 6. Market Share Analysis

8. PET/MR EQUIPMENT SEGMENT

  • 1. Measurements
  • 2. Unit Shipment Forecast
  • 3. Revenue Forecast
  • 4. Trend Analysis
  • 5. Market Share
  • 6. Market Share Analysis

9. KEY PRODUCTS AND PARTICIPANTS

  • 1. Analysis of Hybrid Molecular Imaging Products
  • 2. Actively Marketed PET/CT Products in 2016
  • 3. Actively Marketed PET/MR Products in 2016
  • 4. Actively Marketed SPECT/CT Products in 2016

10. LATEST TRENDS AMONG THE BIG THREE COMPETITORS-PHILIPS HEALTHCARE

  • 1. Digital PET-The Next Chapter in Nuclear Imaging

11. GE HEALTHCARE

  • 1. GE Healthcare-Key Technology Trends
  • 2. GE Debuts DiscoveryTM MI PET/CT at SNMMI 2016
  • 3. Launch of Discovery IQ PET/CT by GE
  • 4. GE Launches First General Purpose Digital SPECT/CT

12. SIEMENS HEALTHINEERS

  • 1. Siemens Debuts Mobile Biograph Horizon PET/CT
  • 2. Siemens Debuts Latest Version of syngo.via

13. COMPANIES TO LOOK OUT FOR

  • 1. NeuSoft
  • 2. Toshiba America Medical Systems
  • 3. Molecular Dynamics
  • 4. UltraSPECT

14. OTHER ISSUES IMPACTING GROWTH OF MOLECULAR IMAGING

  • 1. Upgradeability and Intra Modality Competition
  • 2. Nuclear Medicine Physicians Face Employment Challenges

15. KEY TECHNOLOGY AND INDUSTRY TRENDS

  • 1. Technology Trends-PET/CT & SPECT/CT
  • 2. Industry Trends-Advancements in Brain Imaging Using SPECT
  • 3. Industry Trends-PET Scanning and Alzheimer's Disease
  • 4. Industry Trends-CMS Approves Funding for PET Amyloid Study
  • 5. Industry Trends-Myocardial Perfusion Imaging: PET vs. SPECT
  • 6. Industry Trends-Myocardial Perfusion Imaging: PET vs. SPECT (continued)

16. DRIVERS AND RESTRAINTS-TOTAL RADIOPHARMACEUTICALS MARKET

  • 1. Market Drivers
  • 2. Development of New Radiopharmaceuticals
  • 3. Adopting a Cyclotron-based Approach
  • 4. Mo-99 Production-Key Challenges and Potential Solutions
  • 5. Market Restraints
  • 6. Pricing and Reimbursement of Tc-99m-Key Challenges
  • 7. High Entry Barriers Limit the Number of Participants

17. PET RADIOPHARMACEUTICALS SEGMENT

  • 1. Measurements
  • 2. Procedure Forecast
  • 3. Revenue Forecast
  • 4. Trend Analysis
  • 5. Market Share
  • 6. Market Share Analysis

18. SPECT RADIOPHARMACEUTICALS SEGMENT

  • 1. Measurements
  • 2. Procedure Forecast
  • 3. Revenue Forecast
  • 4. Trend Analysis
  • 5. Market Share
  • 6. Market Share Analysis

19. KEY PRODUCTS AND PARTICIPANTS

  • 1. Analysis of PET and SPECT Radiopharmaceuticals
  • 2. Key Market Participants and Main Product Lines
  • 3. Key Market Participants and Main Product Lines (continued)
  • 4. Key Market Participants and Main Product Lines (continued)

20. KEY COMPANIES TO LOOK OUT FOR

  • 1. Siemens PETNET
  • 2. IBA Molecular
  • 3. Ionetix

21. KEY INDUSTRY TRENDS

  • 1. Jubilant Draximage Develops Rubidium Generator
  • 2. Northstar Medical Isotopes to Produce Mo-99
  • 3. FDA Approves Gallium 68 Dotatate Kit-NETSPOT
  • 4. FDA Approves Axumin PET Radiopharmaceutical
  • 5. Axumin-Safety and Efficacy Parameters
  • 6. CMS Rejection of NaF-18 PET Scan Reimbursement
  • 7. Cardiac PET Perfusion Agents Industry-A Snapshot

22. ROLE OF NEW RADIOPHARMACEUTICALS IN ONCOLOGY

  • 1. Role of Radiopharmaceuticals in Oncology Clinical Trials
  • 2. 18F-CFA-The Next Frontier in Cancer Treatment
  • 3. New PET Tracers for Clinical Use in Oncology

23. THE LAST WORD

  • 1. The Last Word-3 Big Predictions: Molecular Imaging
  • 2. The Last Word-3 Big Predictions: Radiopharmaceuticals
  • 3. Legal Disclaimer

24. APPENDIX

  • 1. Glossary of Terms-Molecular Imaging
  • 2. Glossary of Terms-Radiopharmaceuticals
  • 3. Methodology
Back to Top